Clinical Trials Browser

Phase 2 × Fractures, Spontaneous × Plasma cell × Clear all

NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency